|Description||A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1.|
|Synonyms||(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(2,6-diethylanilino)-2-oxoethyl]-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid; (2R-(2alpha,3beta,4alpha)-4-(1,3-benzodioxol-5-yl)-1-(2-(2,6-diethylphenyl)amino)-2-oxoethyl)-2-(4-propoxyphenyl)-3-pyrrolidinecarboxylic acid; A 192621; A-192621; A192621|
Macitentan n-butyl analogue
Macitentan n-butyl analogue is a derivative of Macitentan, which is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle.
T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...
Sitaxsentan, also called as IPI 1040 or TBC 11251, is a potent orally bioactive ET receptor antagonist that has a long duration of action (t1/2, 5–7 hours) and ...
CI 1020 has been found to be a novel endothelin-A receptor antagonist and could be used as an antihypertensive agent.
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
Darusentan is a selective endothelin-1 receptor A inhibitor. Darusentan is identified as the treatment of congestive heart failure, hypertension and cancers. It...
Endothelin 2 (human)
Endothelin 2 is a ligand for the endothelin (ET) receptors and a potent vasoconstrictor mainly found in the kidney and intestine.
Endothelin 3 (human, rat)
Endothelin 3 is a ligand of the endothelin (ET) receptors and a potent vasoconstrictor. Endothelin 3 increases blood pressure in spontaneously hypertensive and ...